MRK vs MS: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
Merck & Co., Inc. · Healthcare
$119.07
-4.0% upside to fair value
Grade D
High Quality
VS
Morgan Stanley · Financial Services
$189.30
-30.5% upside to fair value
Grade C
High Quality
QuantHub Verdict
MRK has more upside to fair value
(-4.0%).
MRK trades at a lower forward P/E
(16.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
MS |
| Current Price |
$119.07 |
$189.30 |
| Fair Value Estimate |
$114.30 |
$131.49 |
| Upside to Fair Value |
-4.0%
|
-30.5%
|
| Market Cap |
$294.4B |
$300.6B |
| Forward P/E |
16.2x
|
16.4x
|
| EV / EBITDA |
12.6x
|
24.4x
|
| Price / Sales |
4.5x
|
2.5x
|
| Price / FCF |
23.8x
|
-16.8x
|
| Revenue Growth YoY |
+5.0%
|
+18.8%
|
| Gross Margin |
81.5%
|
58.0%
|
| Operating Margin |
41.2%
|
19.5%
|
| Return on Equity |
36.2%
|
16.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.2%
|
—
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, particularly oncology and vaccines. The company benefits from a strong business quality characterized by a durable competitive moat, high gross margins of 81.5%, and a robust return on equity of 36.2%. Despite these strengths, the stock is currently fairly valued but slightly overvalued by 4% relative to its…
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Accumulation Zones
| Metric |
MRK |
MS |
| Zone Low |
$85.72 |
$98.62 |
| Zone High |
$97.16 |
$111.77 |
| In Buy Zone? |
No
|
No
|